Skip to main content
Journal cover image

Phase II study of fludarabine phosphate in patients with advanced colorectal carcinoma.

Publication ,  Journal Article
Ajani, JA; Abbruzzese, JL; Faintuch, JS; Blackburn, R; Levin, B; Boman, BM
Published in: Invest New Drugs
April 1988

For phase II studies in patients with solid tumors, the National Cancer Institute recommended that the starting dose of fludarabine phosphate be 20 mg/m2/day as a short intravenous infusion for 5 days every 21 days. Twenty-one patients with untreated, advanced, measurable colorectal carcinoma received fludarabine phosphate as a 30-minute infusion at a median dose of 25 mg/m2/day (range 15-35 mg/m2/day) for 5 consecutive days repeated every three weeks. Antitumor response was evaluated following two courses of therapy. No patient achieved complete or partial response. Minor regression of lung metastases occurred for less than 12 weeks in one patient. Therapy was generally well tolerated. Frequent toxicities included lymphopenia, mild nausea and vomiting, mucositis, and anorexia. One patient died of sepsis, bleeding, and progressive disease while she was severely myelosuppressed. Neurotoxicity was not observed in any patient. Fludarabine phosphate at this schedule and dose range is inactive against colorectal carcinoma.

Duke Scholars

Published In

Invest New Drugs

DOI

ISSN

0167-6997

Publication Date

April 1988

Volume

6

Issue

1

Start / End Page

47 / 50

Location

United States

Related Subject Headings

  • Vidarabine Phosphate
  • Rectal Neoplasms
  • Oncology & Carcinogenesis
  • Middle Aged
  • Male
  • Humans
  • Female
  • Drug Evaluation
  • Colonic Neoplasms
  • Arabinonucleotides
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Ajani, J. A., Abbruzzese, J. L., Faintuch, J. S., Blackburn, R., Levin, B., & Boman, B. M. (1988). Phase II study of fludarabine phosphate in patients with advanced colorectal carcinoma. Invest New Drugs, 6(1), 47–50. https://doi.org/10.1007/BF00170780
Ajani, J. A., J. L. Abbruzzese, J. S. Faintuch, R. Blackburn, B. Levin, and B. M. Boman. “Phase II study of fludarabine phosphate in patients with advanced colorectal carcinoma.Invest New Drugs 6, no. 1 (April 1988): 47–50. https://doi.org/10.1007/BF00170780.
Ajani JA, Abbruzzese JL, Faintuch JS, Blackburn R, Levin B, Boman BM. Phase II study of fludarabine phosphate in patients with advanced colorectal carcinoma. Invest New Drugs. 1988 Apr;6(1):47–50.
Ajani, J. A., et al. “Phase II study of fludarabine phosphate in patients with advanced colorectal carcinoma.Invest New Drugs, vol. 6, no. 1, Apr. 1988, pp. 47–50. Pubmed, doi:10.1007/BF00170780.
Ajani JA, Abbruzzese JL, Faintuch JS, Blackburn R, Levin B, Boman BM. Phase II study of fludarabine phosphate in patients with advanced colorectal carcinoma. Invest New Drugs. 1988 Apr;6(1):47–50.
Journal cover image

Published In

Invest New Drugs

DOI

ISSN

0167-6997

Publication Date

April 1988

Volume

6

Issue

1

Start / End Page

47 / 50

Location

United States

Related Subject Headings

  • Vidarabine Phosphate
  • Rectal Neoplasms
  • Oncology & Carcinogenesis
  • Middle Aged
  • Male
  • Humans
  • Female
  • Drug Evaluation
  • Colonic Neoplasms
  • Arabinonucleotides